HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pedro Pimentel Selected Research

Cyclophosphamide (Cytoxan)

6/2003Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pedro Pimentel Research Topics

Disease

4Graft vs Host Disease (Graft-Versus-Host Disease)
10/2007 - 07/2002
1Lipoid Nephrosis (Glomerulonephritis, Minimal Change)
10/2007
1Nephrotic Syndrome (Syndrome, Nephrotic)
10/2007
1Proteinuria
10/2007
1Bronchiolitis Obliterans Syndrome
10/2007
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2003
1Liver Diseases (Liver Disease)
06/2003
1Hematologic Neoplasms (Hematological Malignancy)
06/2003

Drug/Important Bio-Agent (IBA)

1Mycophenolic Acid (Cellcept)FDA LinkGeneric
10/2007
1Prednisolone (Predate)FDA LinkGeneric
10/2007
1Immunosuppressive Agents (Immunosuppressants)IBA
10/2007
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
06/2003
1Busulfan (Busulfex)FDA Link
06/2003

Therapy/Procedure

3Transplantation
10/2007 - 07/2002
1Stem Cell Transplantation
10/2007
1Aftercare (After-Treatment)
10/2007
1Hematopoietic Stem Cell Transplantation
06/2003